PITTSBURGH, Aug. 6, 2024
/PRNewswire/ - MolecuLight Corp., the global leader in fluorescence
imaging technology for real-time detection of harmful bacteria in
wound care, announces the publication of peer-reviewed clinical
research highlighting the transformative power of MolecuLight in
healing more pressure injuries with fewer infection complications
among 167 Medicare beneficiaries across 55 US-based Long Term Care
and Skilled Nursing Facilities.
Published by Martha R. Kelso and
colleagues, the article entitled "Improving Wound Healing and
Infection Control in Long-term Care with Bacterial Fluorescence
Imaging" is featured in the latest edition of Advances in Skin
& Wound Care journal. The authors report an impressive
improvement in pressure injury outcomes among incredibly complex
and healing-challenged patients. This is a testament to the power
of MolecuLight technology, which continues to prove its
effectiveness even in the most challenging patient base.
When comparing the outcomes of patients that were treated per
standard of care approach alone with those in which MolecuLight
real-time fluorescence was integrated into that care, those in the
MolecuLight-imaged group saw 71% more wounds healed by 12 weeks,
healed 28% faster, and were 1.8 times more likely to heal their
wound by 12-weeks. The researchers also investigated the incidence
of severe infection complications including cellulitis,
osteomyelitis, gangrene, sepsis, and wound-related hospitalization,
reporting a 75% decrease in infection complications when patient
care was guided with the help MolecuLight.
"We are very excited to share with the world through concrete
findings what we have been experiencing firsthand with our LTC/SNF
patients," remarks Martha R. Kelso,
lead author of this study "The positive effects that the
MolecuLight technology has on all patients, even those who are
severely sick and compromised, is outstanding. Increasing healing
rates, shortening healing times and avoiding complications IS how
you make a difference. All patients deserve the best! I hope that
as these remarkable outcomes are shared with our wound care
colleagues, they too can be part of this much needed disruption to
wound care."
Anil Amlani, CEO of MolecuLight, expressed his enthusiasm about
these groundbreaking findings. "We are thrilled to see such
compelling evidence of the impact our technology can have on
patient outcomes, particularly in such a vulnerable and
systematically neglected patient population." He continues, "The
significant improvements in wound healing and the dramatic
reduction in infection complications underscore the potential of
MolecuLight to revolutionize wound care, in any place of service
and against the most challenging of clinical backgrounds. This
research is another example of our commitment to improving patient
care and advancing the field of wound management."
About MolecuLight Inc and its wound imaging devices
MolecuLight Inc. is a privately owned medical imaging
company with a global presence that manufactures and commercializes
the MolecuLight i:X® and DX™
wound imaging devices. These are the only class II
FDA-cleared point-of-care imaging devices for the real-time
detection of elevated bacterial burden in wounds. They also
provide accurate digital wound measurement for comprehensive wound
management, supported by strong clinical evidence including over
100 peer-reviewed publications.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculights-profound-impact-on-wound-healing-highlighted-in-breaking-clinical-research-302213793.html
SOURCE MolecuLight